- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00071032
Safety and Effectiveness of Two Blood Transfusion Strategies in Surgical Patients With Cardiovascular Disease (FOCUS)
Functional Outcomes in Cardiovascular Patients Undergoing Surgical Hip Fracture Repair (FOCUS)
Study Overview
Status
Conditions
Detailed Description
BACKGROUND:
Red blood cell transfusions are an extremely common medical intervention in both the United States and worldwide; over 14 million units of blood are transfused in the United States. Between 60 and 70 percent of all blood is transfused in the surgical setting. Despite the common use of red blood cell transfusions, the threshold for transfusion has not been adequately evaluated and is very controversial. A decade ago, the standard of care was to administer a peri-operative transfusion whenever the hemoglobin (Hgb) level fell below 10 g/dl (the "10/30 rule"). Concerns about the safety of blood, especially with respect to HIV and hepatitis, and the absence of data to support a 10 g/dl threshold led to the current standard of care, which is to administer blood transfusions based on the presence of symptoms, and not a specific Hgb/hematocrit level. However, there have not been any randomized clinical trials done with surgical patients that have tested the efficacy and safety of withholding blood until the patient develops symptoms, or the "10/30" approach to transfusion. Patients with underlying cardiovascular disease are at greatest risk of adverse effects from reduced Hgb levels.
DESIGN NARRATIVE:
This is a multi-center randomized trial to test the effectiveness of a transfusion strategy that maintains postoperative Hgb levels above 10 g/dl (liberal transfusion) in improving patient outcome. This will be compared to the restrictive (symptomatic) transfusion strategy in which blood transfusion is withheld until the patient develops symptoms of anemia or Hgb less than 8 g/dL. Participants will be randomly assigned to one of the two transfusion strategies. The liberal (10 g/dl) threshold strategy will use enough red blood cell units to maintain Hgb levels at or above 10 g/dl through hospital discharge. Restrictive (Symptomatic) transfusion strategy patients will receive red blood cell transfusions for symptoms of anemia, although transfusion is also permitted, but not required, if the Hgb level falls below 8 g/dl. Outcomes will include functional recovery (primary outcome: ability to walk 10 feet across a room without human assistance or death 60 days post-randomization), lower extremity activities of daily living and instrumental activities of daily living, survival up to 60-days and long-term, disposition (i.e., nursing home placement), and postoperative complications (e.g., myocardial infarction, unstable angina, or death in hospital, pneumonia, wound infection, thromboembolism, stroke).
Ambulation at 60 days is known to be highly predictive of ultimate functional outcome as well as of mortality at one year. Because inability to walk has such important implications for quality of life, and because it is a common problem, it far outweighs the small risk of viral infection or other complications from transfusion in elderly patients.
The trial will also evaluate the effect of transfusion threshold on postoperative risk of acute cardiac ischemia. The strategy will be to enhance surveillance for ischemic events by increasing the number of EKG and serum troponin measurements beyond those already called for in the original FOCUS protocol.
There is an ancillary study to the trial (R01 HL085706) to examine delirium as an outcome in a subsample of 139 patients. We will assess short-term (in hospital) and longer-term (after 30 days) severity of delirium.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
New Jersey
-
New Brunswick, New Jersey, United States, 08903
- University Medicine & Dentistry of NJ
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Has undergone surgical repair for a hip fracture
- Has a postoperative Hgb level below 10 g/dL within three days of surgery
- Diagnosis of cardiovascular disease (e.g., coronary artery disease, congestive heart failure, stroke or transient ischemic attack, or peripheral vascular disease) or cardiovascular risk factors (e.g., diabetes mellitus, hypertension, hypercholesterolemia, tobacco use, or creatinine levels greater than 2.0 mg/dL)
Exclusion Criteria:
- Unable to walk prior to hip fracture
- Declines blood transfusions
- Suffered multiple traumas
- Pathologic fracture of the hip due to malignancy
- Clinically recognized acute myocardial infarction within the 30 days prior to study entry
- Previously participated in the trial and fractured the other hip
- Symptoms associated with anemia (e.g., ischemic chest pain) or actively bleeding at the time of randomization
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Liberal (10 g/dL) Transfusion Strategy
Transfusion strategy that maintains postoperative Hgb levels above 10 g/dL.
|
This transfusion strategy will maintains postoperative Hgb levels above 10 g/dL.
This threshold strategy will use enough red blood cell units to maintain Hgb levels at or above 10 g/dL through hospital discharge or up to 30 days after randomization.
|
Active Comparator: 2
Symptomatic transfusion strategy, a more conservative strategy, in which blood transfusion is withheld until the patient develops symptoms of anemia.
|
Transfusion is withheld until the patient develops symptoms from anemia (i.e., chest pain or ECG changes thought to be ischemic, congestive heart failure, unexplained tachycardia or hypotension unresponsive to fluids) or until the hemoglobin level falls below 8 g/dL.
Transfusion is permitted, but is not mandatory, if the hemoglobin level falls below 8 g/dL.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Inability to Walk 10 Feet or Across a Room Without Human Assistance or Death
Time Frame: 60 days after randomization
|
ascertained via telephone follow-up
|
60 days after randomization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Myocardial Infarction, Unstable Angina, or Death for Any Reason
Time Frame: In-hospital
|
In-hospital
|
|
Mortality at 30 Days
Time Frame: 30 days
|
30 days
|
|
Mortality at 60 Days
Time Frame: 60 Days
|
60 Days
|
|
Composite Outcomes (a) Death, Myocardial Infarction, or Pneumonia and b) Death, Myocardial Infarction, Pneumonia, Thromboembolism, or Stroke
Time Frame: In-hospital
|
In-hospital
|
|
Myocardial Infarction
Time Frame: In-hospital
|
In-hospital
|
|
Postoperative Complications (e.g., Wound Infection, Thromboembolism, Stroke)
Time Frame: In hospital
|
In hospital
|
|
Disposition Status (i.e., Nursing Home Placement)
Time Frame: 60 days
|
Nursing Home Residence
|
60 days
|
Function - Lower Extremity Activities of Daily Living,at 30 Days
Time Frame: 30 days
|
Using the Functional Status Index, score range 0 to 11, higher scores indicate greater dependency
|
30 days
|
Function - Instrumental Activities of Daily Living, at 30 Days
Time Frame: 30 days
|
Using the Older Americans Resources and Services Functional Assessment Questionnaire, score range from 0 to 4, higher scores indicating greater dependency
|
30 days
|
Function - Fatigue/Energy, at 30 Days
Time Frame: 30 days
|
Using the Functional Assessment of Chronic Illnesses Therapy-Fatigue, score range from 0 to 52, higher scores indicating greater level of energy
|
30 days
|
Function - Lower Extremity Activities of Daily Living. at 60 Days
Time Frame: 60 Days
|
Scale range 0 to 11, higher scores indicate greater dependency
|
60 Days
|
Function - Instrumental Activities of Daily Living, at 60 Days
Time Frame: 60 Days
|
Scale range 0 to 11, higher scores indicate greater dependency
|
60 Days
|
Function - Fatigue/Energy, at 60 Days
Time Frame: 60 Days
|
Scale ranging from 0 to 52, higher scores indicating greater level of energy
|
60 Days
|
Length of Stay in Hospital for United States Participants
Time Frame: Days from randomization to discharge
|
Days from randomization to discharge
|
|
Length of Stay in Hospital for Canadian Participants
Time Frame: Days from randomization to discharge
|
Days from randomization to discharge
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Jeffrey L. Carson, MD, University Medicine & Dentistry of NJ
- Principal Investigator: Michael Terrin, University of Maryland, College Park
Publications and helpful links
General Publications
- Carson JL, Stanworth SJ, Dennis JA, Trivella M, Roubinian N, Fergusson DA, Triulzi D, Doree C, Hebert PC. Transfusion thresholds for guiding red blood cell transfusion. Cochrane Database Syst Rev. 2021 Dec 21;12(12):CD002042. doi: 10.1002/14651858.CD002042.pub5.
- Carson JL, Terrin ML, Magaziner J, Chaitman BR, Apple FS, Heck DA, Sanders D; FOCUS Investigators. Transfusion trigger trial for functional outcomes in cardiovascular patients undergoing surgical hip fracture repair (FOCUS). Transfusion. 2006 Dec;46(12):2192-206. doi: 10.1111/j.1537-2995.2006.01056.x. No abstract available.
- Carson JL, Terrin ML, Noveck H, Sanders DW, Chaitman BR, Rhoads GG, Nemo G, Dragert K, Beaupre L, Hildebrand K, Macaulay W, Lewis C, Cook DR, Dobbin G, Zakriya KJ, Apple FS, Horney RA, Magaziner J; FOCUS Investigators. Liberal or restrictive transfusion in high-risk patients after hip surgery. N Engl J Med. 2011 Dec 29;365(26):2453-62. doi: 10.1056/NEJMoa1012452. Epub 2011 Dec 14.
- Carson JL, Sieber F, Cook DR, Hoover DR, Noveck H, Chaitman BR, Fleisher L, Beaupre L, Macaulay W, Rhoads GG, Paris B, Zagorin A, Sanders DW, Zakriya KJ, Magaziner J. Liberal versus restrictive blood transfusion strategy: 3-year survival and cause of death results from the FOCUS randomised controlled trial. Lancet. 2015 Mar 28;385(9974):1183-9. doi: 10.1016/S0140-6736(14)62286-8. Epub 2014 Dec 9.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Ischemia
- Pathologic Processes
- Necrosis
- Myocardial Ischemia
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Embolism and Thrombosis
- Myocardial Infarction
- Infarction
- Heart Diseases
- Stroke
- Cardiovascular Diseases
- Hematologic Diseases
- Thromboembolism
Other Study ID Numbers
- 159
- U01HL073958-06 (U.S. NIH Grant/Contract)
- U01HL073958 (U.S. NIH Grant/Contract)
- U01HL074815 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myocardial Infarction
-
Azienda ULSS 5 PolesanaUniversity of PadovaUnknownMyocardial Infarction, Acute | ST Segment Elevation Myocardial Infarction | Non-ST Elevation Myocardial Infarction (nSTEMI)Italy
-
University Medical Centre LjubljanaCompletedCardiac Arrest | Postresuscitation Syndrome | Myocardial Infarction (ST-Elevation Myocardial Infarction and Non-ST-Elevation Myocardial Infarction)Slovenia
-
Fundacio Privada Mon Clinic BarcelonaMiracor Medical SANot yet recruiting
-
Stiftung Institut fuer HerzinfarktforschungGlaxoSmithKline; University Hospital Muenster; Klinikum NürnbergCompletedMyocardial Infarction | ST-Elevation Myocardial Infarction | Non-ST-Elevation Myocardial InfarctionGermany
-
Bispebjerg HospitalOdense University Hospital; Zealand University Hospital; Hvidovre University... and other collaboratorsRecruitingST Elevation Myocardial Infarction | Acute Myocardial Infarction | Non-ST Elevation Myocardial Infarction (nSTEMI)Denmark
-
Population Health Research InstituteCanadian Institutes of Health Research (CIHR); Boston Scientific CorporationActive, not recruitingST Elevation Myocardial Infarction | Non ST Elevation Myocardial InfarctionCanada
-
University of LeedsUniversity College, LondonCompletedST-elevation Myocardial Infarction | Non ST-elevation Myocardial Infarction
-
Barts & The London NHS TrustUniversity College, London; Queen Mary University of LondonCompletedAcute Myocardial InfarctionSwitzerland, Denmark, United Kingdom
-
Karolinska InstitutetUppsala University; The Swedish Research CouncilActive, not recruitingST Elevation Myocardial Infarction | Acute Myocardial Infarction | Non-ST Elevation Myocardial InfarctionSweden
-
Oslo University HospitalVestre Viken Hospital Trust; University of Oslo; University Hospital of North... and other collaboratorsActive, not recruitingST Elevation Myocardial Infarction | Acute Myocardial Infarction | Non-ST Elevation Myocardial InfarctionNorway
Clinical Trials on Liberal (10 g/dL) Transfusion Strategy
-
Guangdong Provincial People's HospitalNot yet recruitingValve Heart Disease | Cardiac Surgery With Cardiopulmonary BypassChina
-
University of Sao PauloCompleted
-
Unity Health TorontoRecruitingCardiac Surgery | Heart | Postoperative | DisorderCanada, Russian Federation
-
Aretaieion University HospitalCompletedSurgery | Cytokine Storm | Infection After Transfusion | Transfusion-related Immunomodulation ReactionGreece
-
Erasme University HospitalEuropean Society of Intensive Care MedicineCompletedBlood Transfusion | Acute Brain InjuryBelgium
-
Unity Health TorontoCompletedDisorder; Heart, Functional, Postoperative, Cardiac SurgeryCanada, Spain, United States, Israel, Australia, New Zealand, Denmark, Colombia, Egypt, Germany, Singapore, Switzerland, China, Brazil, Greece, India, Malaysia, Romania, South Africa
-
St. Justine's HospitalNancy Robitaille, MDTerminated
-
Ottawa Hospital Research InstituteCanadian Institutes of Health Research (CIHR)RecruitingSubarachnoid Hemorrhage, AneurysmalUnited States, Australia, Canada
-
Ottawa Hospital Research InstituteCompletedSubarachnoid HemorrhageCanada
-
RenJi HospitalRecruitingPediatric Patients Who Need Liver TransplantationChina